Ophthalmology

A total solar eclipse will cross 15 states on April 8, 2024. Durga Borkar, MD, MMCi shares how to communicate eye safety tips and prepare to treat anyone who does present with solar retinopathy.

Solar retinopathy is caused by prolonged or high intensity exposure of the fovea centralis to light energy. Suspected cases of solar retinopathy may require urgent referral to an ophthalmologist for diagnosis, and to eliminate treatable causes for central visual disturbance.

Viewing the solar eclipse without proper eye protection can pose hazards, and ophthalmologists can educate patients about the importance of using certified solar viewing glasses or other safe viewing methods.

New members bring a wealth of experience and expertise from various sectors within the ophthalmology, pharmaceutical, and healthcare fields, further strengthening the Ophthalmology Foundation's mission.

Wang and colleagues conducted a retrospective case series patients with full-thickness macular holes.

The investigators explained that the survival rate of patients with retinoblastoma has improved significantly as a result of intra-arterial chemotherapy and enucleation surgery.

Ophthalmologists can educate their patients about the importance of using certified solar viewing glasses or other safe viewing methods.

Ferrone’s role will be effective as of March 18, 2024.

The company has divested its Coherus Ophthalmology subsidiary to Sandoz, Inc. for upfront all-cash consideration of $170 million.

The supplement is specifically crafted to promote healthy intraocular pressure (IOP), nurturing the well-being of retinal ganglion cells, and sustain the health of the retinal nerve fiber layer while boosting memory and concentration.

Products under the terms of the agreement include VERKAZIA, Cationorm PLUS, VEVYE, IHEEZO, and ZERVIATE.

iCRx is set to release the One Minute Eye Exam in April, potentially changing the way ophthalmologists and optometrists conduct eye examinations for corrective lenses.

OK-101 is the first IND clearance granted by the FDA for a drug to begin clinical studies specifically to treat patients suffering with neuropathic corneal pain.

A new study found that only a little over half of school-aged children participants underwent vision screening within the past two years, highlighting gaps in eye care access.

Sir Jules Thorn Charitable Trust's investment will support a state-of-the-art, eye health research facility, opening in 2027.

A team of neuroscientists at Johns Hopkins show how specialized cells signal the presence of light simultaneously in two distinct ways.

The agreement settles Zeiss’s lawsuit against Topcon’s US-based subsidiaries that had been set to start this month in US federal court for the Northern District of California.

In a news release, the FDA noted these are copycat eye drop products that consumers can easily mistake for Bausch + Lomb’s Lumify brand eye drops, an over-the-counter product approved for redness relief.

Glenn Yiu, MD, PhD, was chosen for this grant. Yiu is a retinal specialist and clinician-scientist currently a professor of ophthalmology at the University of California, Davis.

A University of Houston professor found that the excitement over the results of LLR as a treatment option for patients with myopia may have come too soon, before its efficacy was confirmed.

According to the company, Eyconis Inc. is developed with a $150 million commitment from external investors.

Sanders is affiliated with the Retina Group of Washington (RGW) and PRISM Vision Group. He is the first African American and the first PRISM-affiliated physician to serve as president of the ASRS.

A recent study found that despite worldwide reports of ocular inflammatory events being reported after patients received COVID-19 vaccinations, a low amount has been reported in the UK.

According to the companies, the deal also includes Coherus’ CIMERLI biologics license application, ophthalmology sales and select field reimbursement teams. Coherus will now focus on its oncology business.

Evaluating injections of anti-VEGF drugs into the intra-anterior chamber may be a viable alternative, but further study is required.

Consensus, awareness, and a CVI registry: top priorities of the trans-NIH event

The combined organization will support all aspects of ophthalmic clinical research, from front of the eye to back of the eye, leveraging an even larger team of experts with centuries of collective experience in ophthalmology.